60966-36-1

Basic information

• Product Name: 21-hydroxy-20-methylpregn-4-en-3-one
• Synonyms: 21-hydroxy-20-methylpregn-4-en-3-one;20-(Hydroxymethyl)pregna-4-ene-3-one;20-Hydroxymethylpregn-4-en-3-one;Pregn-4-en-3-one, 21-hydroxy-20-methyl-
• CAS NO: 60966-36-1
• Molecular Formula: C₂₂H₃₄O₂
• Molecular Weight: 330.50416
• EINECS: 262-543-1
• Mol File: 60966-36-1.mol

Chemical Properties

• Boiling Point: 464.1°C at 760 mmHg
• Flash Point: 197.5°C
• Appearance: /
• Density: 1.07g/cm³
• Vapor Pressure: 1.45E-10mmHg at 25°C
• Refractive Index: 1.546
• PKA: 14.97±0.10(Predicted)
• CAS DataBase Reference: 21-hydroxy-20-methylpregn-4-en-3-one(CAS DataBase Reference)
• NIST Chemistry Reference: 21-hydroxy-20-methylpregn-4-en-3-one(60966-36-1)
• EPA Substance Registry System: 21-hydroxy-20-methylpregn-4-en-3-one(60966-36-1)

Safety Data

• Hazardous Substances Data: 60966-36-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
21-Hydroxy-20-methylpregn-4-en-3-one is used as a pharmaceutical intermediate for the synthesis of various steroidal drugs. It serves as a key building block in the production of corticosteroids, which have anti-inflammatory and immunosuppressive properties, and are used to treat a wide range of conditions, including allergies, asthma, and autoimmune diseases.
Used in Hormone Replacement Therapy:
21-Hydroxy-20-methylpregn-4-en-3-one is used as a hormone precursor in hormone replacement therapy (HRT) for women experiencing menopause. It helps in maintaining the hormonal balance and alleviates symptoms such as hot flashes, night sweats, and vaginal dryness.
Used in Veterinary Medicine:
21-Hydroxy-20-methylpregn-4-en-3-one is used as a veterinary drug to induce estrus and synchronize ovulation in livestock, improving reproductive efficiency and overall productivity in the agricultural industry.
Used in Research and Development:
21-Hydroxy-20-methylpregn-4-en-3-one is used as a research compound in the development of new drugs and therapies targeting various diseases and conditions. Its unique structure and biological activities make it a valuable tool for understanding the mechanisms of action of steroid hormones and their potential applications in medicine.

InChI:InChI=1/C22H34O2/c1-14(13-23)18-6-7-19-17-5-4-15-12-16(24)8-10-21(15,2)20(17)9-11-22(18,19)3/h12,14,17-20,23H,4-11,13H2,1-3H3/t14?,17-,18+,19-,20-,21-,22+/m0/s1

Upstream product

• 24254-01-1 20β-carboxyaldehyde-4-pregnen-3-one 
• 3986-89-8 (20S)-3-oxopregn-4-ene-20-carboxaldehyde 

Downstream Products

• 24377-48-8 22-(piperidin-1-yl)-23,24-dinorchola-4,20⁽²²⁾-dien-3-one 
• 57-83-0 Progesterone 

Relevant articles and documents

Amines useful in producing pharmaceutically active CNS compounds

Disclosed are Δ9(11) -steroids (VI) and amino substituted steroids (XI) which contain an amino group attached to the terminal carbon atom of the C17 -side chain, more particularly amino steroids (Ia and Ib), aromatic steroids (II), Δ16 -steroids (IIIa and IIIb), reduced A-ring steroids (IV), Δ17(20) -steroids (Va and Vb) and Δ9(11) -steroids (VI) which are useful as pharmaceutical agents for treating a number of conditions.

Amines useful in producing pharmaceutically active CNS compounds

Disclosed are Δ9(11) -steroids (VI) and amino substituted steroids (XI) which contain an amino group attached to the terminal carbon atom of the C17 -side chain, more particularly amino steroids (Ia and Ib), aromatic steroids (II), Δ16 -steroids (IIIa and IIIb), reduced A-ring steroids (IV), Δ17(20) -steroids (Va and Vb) and Δ9(11) -steroids (VI) which are useful as pharmaceutical agents for treating a number of conditions.

PHOSPHINIC ACID SUBSTITUTED STEROIDS AS INHIBITORS OF STEROID 5 ALPHA-REDUCTASE

The invention relates to 3-phosphinic acid steroidal compounds, pharmaceutical compositions containing these compounds, and methods of using these compounds to inhibit steroid 5alpha-reductase.

Steriod 5-alpha-reductase inhibitors

Invented are substituted acrylate analogues of steroidal synthetic compounds, pharmaceutical compositions containing these compounds, and methods of using these compounds to inhibit steroid 5-α-reductase. Also invented are intermediates used in preparing these compounds.

Steroid 5-alpha-reductase inhibitors

[From equivalent EP0289327A3] Compounds of formula (I) : ψψ in which, inter alia, R± is H or C±±±alkyl and M is O or S, processes for their preparation, pharmaceutical compositions containing then and their use as inhibitors of 5-à-reductase in the treatment in the reduction of prostate size.ψ

PHOSPHONIC ACID SUBSTITUTED STEROIDS AS STEROID 5 ALPHA-REDUCTASE INHIBITORS

Invented are substituted acrylate analogues of steroidal synthetic compounds, pharmaceutical compositions containing the compounds, and methods of using these compounds to inhibit steroid 5 alpha-reductase. Also invented are intermediates used in preparing these compounds

STEROID 5-ALPHA-REDUCTASE INHIBITORS

Invented are substituted acrylate analogues of steroidal synthetic compounds, pharmaceutical compositions containing the compounds, and methods of using these compounds to inhibit steroid 5-alpha-reductase. Also invented are intermediates used in preparing these compounds

C20 Through C26 amino steroids

Disclosed are Δ9 (11)-steroids (VI) and amino substituted steroids of formula (XI) which contain an amino group attached to the terminal carbon atom of the C17-side chain, more particularly amino steroids (Ia and Ib), aromatic steroids (II), Δ16 (11)-steroids (IIIa and IIIb), reduced A-ring steroids (IV), Δ17 (20)-steroids (Va and Vb) and Δ9 (11)-steroids (VI) which are useful as pharmaceutical agents for treating a number of conditions.

STUDIES ON THE CHEMO- AND STEREOSELECTIVITY OF SODIUM BOROHYDRIDE-POLYETHYLENE GLYCOL 400-MEDIATED REDUCTIONS

Chemo- and stereoselectivity of reductions by the NaBH4/polyethylene glycol (PEG) 400 system have been studied and compared to the traditional NaBH4 reductions in methanol.When the stereoselectivity was tested on 3- and 7-keto steroids 1a and 1b, respectively, interesting improvements were observed.Aldehydes were reduced faster than ketones and in the case of 3-oxo-pregn-4-en-20β-carboxaldehyde, 2a, the aldehyde was reduced completely leaving the unsatured ketone moiety unchanged.Absorption on inorganic support or addition of a few cationic species led to inactive or much less active reducing species.

Process for the preparation of 21-hydroxy-20-methylpregnane derivatives

In a process for preparing 21-hydroxy-20-methylpregnane derivatives by fermenting a zoosterol or a phytosterol with a culture of Mycobacterium spec. NRRL B-3683 or NRRL B-3805 or a variant or mutant thereof, an improvement comprises conducting the fermentation at a pH value of 6.0-8.0 in the presence of an amount of borate ions or an organic boron compound effective to increase the yield of the 21-hydroxy-20-methylpregnane derivatives produced.